---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-25-015149"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T09:01:06.785271+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent

## Summary
- Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.
- Antev develops Teverelix, a GnRH antagonist for acute urinary retention and high-CV-risk prostate cancer; targets ~$6B market.
- Patrick J. Mahaffy, former Antev chairman and ex-CEO of Clovis Oncology, appointed to board; receives 25,000 stock options at $1.94 vesting quarterly over 12 months.
- Consideration shares subject to staggered 210-day lock-up (15% released every 30 days from effective registration; final 10% at 210 days).
- Sold 250,000 common shares to Yorkville via SEPA for ~$490,535 net proceeds; proceeds to prepay outstanding debentures.

## SEC filing metadata
- accession: 0001062993-25-015149
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/0001062993-25-015149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-25-015149
- JSON: https://secwatch.observer/filing/0001062993-25-015149.json
- Plain text: https://secwatch.observer/filing/0001062993-25-015149.txt

## Key facts
- M&A Transactions
  Medicus Pharma Ltd. completed an acquisition involving Antev Ltd. for approximately US$3.0 million in cash and 1,603,164 common shares (closed 2025-08-29).
  - Action: acquisition
  - Counterparty: Antev Ltd.
  - Consideration: approximately US$3.0 million in cash and 1,603,164 common shares
  - Closing: 2025-08-29
  source text: On August 29, 2025, Medicus Pharma Ltd. ("Medicus" or the "Company") completed (the "Closing") its previously announced acquisition of Antev Ltd. ("Antev") pursuant to that certain definitive securities exchange agreement, dated as of June 29, 2025 (as amended, the "Definitive Agreement"), by and among the Company, Antev and certain securityholders of Antev (the "Antev Vendors"), pursuant to which the Company acquired (the "Transaction") 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$3.0 million in cash and 1,603,164 common shares of Medicus (the "Consideration Shares").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/0001062993-25-015149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.